Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dicloralurea SCHEMBL134347 | 0.82 | HPGD (0.45) | HPGD | |
| Dicloralurea SCHEMBL6534881 | 0.78 | HPGD (0.41) | HPGD | |
| Dicloralurea SCHEMBL2674558 | 0.76 | HPGD (0.41) | HPGDALDH1A1MAPT | |
| Dicloralurea SCHEMBL3965395 | 0.76 | HPGD (0.40) | HPGDALDH1A1MEN1KMT2A | |
| Dicloralurea SCHEMBL5418303 | 0.74 | HPGD (0.39) | HPGDALDH1A1 | |
| Mecloralurea SCHEMBL547686 | 0.74 | HPGD (0.44) | HPGD | |
| Dicloralurea SCHEMBL17968228 | 0.73 | HPGD (0.41) | HPGD | |
| Dicloralurea SCHEMBL4966646 | 0.71 | HPGD (0.39) | HPGD | |
| Dicloralurea SCHEMBL6289122 | 0.71 | HPGD (0.36) | HPGDALDH1A1 | |
| SCHEMBL25292405 | 0.69 | HPGD (0.47) | HPGDALDH1A1MEN1MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015176025-A9 | DISCOIDAL POLYMERIC NANOCONSTRUCTS AND METHODS OF USE IN CANCER THERANOSTICS | THE METHODIST HOSPITAL (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015176025-A1 | DISCOIDAL POLYMERIC NANOCONSTRUCTS AND METHODS OF USE IN CANCER THERANOSTICS | THE METHODIST HOSPITAL (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-1188768-B1 | LHRH antagonist peptides | UNIV INDIANA RES & TECH CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1725236-A4 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| EP-1751089-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| EP-1725236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-7071165-B2 | LHRH antagonist peptides | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| WO-2005087236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005086873-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20030181385-A1 | LHRH antagonist peptides | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE | 2003-09-25 | — | — | US | disclosed |
| US-20030040482-A1 | LHRH antagonist peptides | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE | 2003-02-27 | — | — | US | disclosed |
| US-6455499-B1 | Methods for treating disorders associated with LHRH activity | INDIANA UNIVERSITY FOUNDATION | 2002-09-24 | — | — | US | disclosed |
| EP-0794961-B1 | LHRH ANTAGONIST PEPTIDES | ADVANCED RES & TECH INST (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6423686-B1 | LHRH antagonist peptides | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE | 2002-07-23 | — | — | US | disclosed |
| EP-1188768-A2 | LHRH antagonist peptides | Advanced Research & Technology Institute (US) | 2002-03-20 | — | — | EP | disclosed |
| US-5843901-A | LHRH antagonist peptides | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0794961-A2 | LHRH ANTAGONIST PEPTIDES | INDIANA UNIVERSITY FOUNDATION (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996040757-A2 | LHRH ANTAGONIST PEPTIDES | INDIANA UNIVERSITY FOUNDATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181385-A1 | LHRH antagonist peptides | LHCGR, GNRHR, PRLHR | HPGD 1464/4885TSHR 43/4885TDP1 4856/4885 |
| US-20030040482-A1 | LHRH antagonist peptides | LHCGR, GNRHR, PRLHR | HPGD 1464/4885TSHR 43/4885TDP1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.